Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyNasser H. Hanna, Paul A. Bunn, Sofia Paul et al.|Journal of Clinical Oncology|2004Cited by 2.4k
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung CancerFred R. Hirsch, Brian R. Holloway, Marileila Varella‐Garcia et al.|Journal of Clinical Oncology|2006Cited by 702
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinibY. Wang, Fred R. Hirsch, Tao Jiang et al.|Annals of Oncology|2018Cited by 217
Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein LevelsBarbara A. Helfrich, Paul A. Bunn|Clinical Cancer Research|2006Cited by 124
A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.Karen Kelly, Paul A. Bunn, Zhaoxing Pan et al.|PubMed|1997Cited by 29